TY - JOUR T1 - Cell cycle abnormalities in lymphoblastoid cell lines derived from patients with obsessive-compulsive disorder JF - medRxiv DO - 10.1101/2020.03.31.20041368 SP - 2020.03.31.20041368 AU - Pravallika Manjappa AU - Safoora Naaz AU - Ravi Kumar Nadella AU - Tulika Shukla AU - Pradip Paul AU - Srinivas Balachander AU - Meera Purushottam AU - Reeteka Sud AU - YC Janardhan Reddy AU - Sanjeev Jain AU - Biju Viswanath Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/04/02/2020.03.31.20041368.abstract N2 - Cell cycle abnormalities have been implicated in the pathology of neuropsychiatric disorders. Anti-obsessional agents like the serotonin reuptake inhibitor (SRI), fluoxetine, are known to cause cell cycle arrest. This study aimed at exploring cell cycle abnormalities in obsessive compulsive disorder (OCD) and the effect of in vitro Fluoxetine on lymphoblastoid cell lines (LCLs) derived from OCD patients and healthy controls. The patients had also been systematically characterized for SRI treatment response. LCLs were treated with 10µM of Fluoxetine for 24 hours and the percentage of cells in each phase of the cell cycle was determined by flow cytometry, after propidium iodide staining, and analysed using the software FlowJo. We observed a lower proportion of cells in the G2/M phase in OCD cases than controls. Among cases, clinical non-responders to SRI treatment had a lower proportion of cells in G2/M phase than the clinical responders. This suggests that there is a reduction of very specific cell cycle phase in OCD; and this difference is more pronounced in clinical non-responders. Although in-vitro fluoxetine treatment reduced the proportion of cells in G2/M phase overall, this was not specific to any group. The findings suggest that cell cycle G2/M phase dysregulation could be peripheral cellular phenotype for OCD, and a marker for SRI non-response in the clinic.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study has been supported by various research grants - from the Department of Biotechnology, Government of India, as part of the Accelerator Program for Discovery in Brain Disorders using Stem cells (ADBS); the Department of Science & Technology (by the DST-INSPIRE Program Faculty grant) to BV; and the OCD Genetics Study (Grant no.GIA/38/2014-DHR) by the Indian Council Medical Research (ICMR), Ministry of Health & Family Welfare, Government of India to BV and YCJR. The authors PM, SN, RKN, PP, SB & RS were/are supported by the ADBS ProgramAuthor DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAvailable by contacting the corresponding author ER -